J. Robert Gillespie

J. Robert Gillespie

Auto-generated profile, based on publicly available information

J. Robert Gillespie

Department of Medicine University of Washington Seattle WA 98195 USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2008 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
KOKayode K. Ojo
Kayode K. Ojo
JGJ. Robert Gillespie
J. Robert Gillespie
ARAaron J. Riechers
Aaron J. Riechers
ANAlberto J. Napuli
Alberto J. Napuli
CVChristophe L. M. J. Verlinde
Christophe L. M. J. Verlinde
WVWesley C. Van Voorhis
Wesley C. Van Voorhis
Development of a safe, effective, and inexpensive therapy for African trypanosomiasis is an urgent priority. In this study, we evaluated the validity of Trypanosoma brucei glycogen synthase kinase 3 (GSK-3) as a potential drug target. Interference with the RNA of either of two GSK-3 homologues in bloodstream-form T. brucei parasites led to growth arrest and altered parasite morphology, demonstrating their requirement for cell survival. Since the growth arrest after RNA interference appeared to be more profound for T. brucei GSK-3 “short” (Tb10.161.3140) than for T. brucei GSK-3 “long” (Tb927.7.2420), we focused on T. brucei GSK-3 short for further studies. T. brucei GSK-3 short with an N-terminal maltose-binding protein fusion was cloned, expressed, and purified in a functional form. The potency of a GSK-3-focused inhibitor library against the recombinant enzyme of T. brucei GSK-3 short, as well as bloodstream-form parasites, was evaluated with the aim of determining if compounds that inhibit enzyme activity could also block the parasites' growth and proliferation. Among the compounds active against the cell, there was an excellent correlation between activity inhibiting the T. brucei GSK-3 short enzyme and the inhibition of T. brucei growth. Thus, there is reasonable genetic and chemical validation of GSK-3 short as a drug target for T. brucei . Finally, selective inhibition may be required for therapy targeting the GSK-3 enzyme, and a molecular model of the T. brucei GSK-3 short enzyme suggests that compounds that selectively inhibit T. brucei GSK-3 short over the human GSK-3 enzymes can be found.

26 February 2008 in Molecular Microbiology
Verified
Journal Article
Open access
PDF file
TATracy L. Arakaki
Tracy L. Arakaki
FBFrederick Buckner
Frederick Buckner
JGJ. Robert Gillespie
J. Robert Gillespie
NMNicholas A. Malmquist
Nicholas A. Malmquist
MPMargaret A. Phillips
Margaret A. Phillips
EMEthan A. Merritt
Ethan A. Merritt
Summary: Nucleotide biosynthesis pathways have been reported to be essential in some protozoan pathogens. Hence, we evaluated the essentiality of one enzyme in the pyrimidine biosynthetic pathway, dihydroorotate dehydrogenase (DHODH) from the eukaryotic parasite Trypanosoma brucei through gene knockdown studies. RNAi knockdown of DHODH expression in bloodstream form T. brucei did not inhibit growth in normal medium, but profoundly retarded growth in pyrimidine‐depleted media or in the presence of the known pyrimidine uptake antagonist 5‐fluorouracil (5‐FU). These results have significant implications for the development of therapeutics to combat T. brucei infection. Specifically, a combination therapy including a T. brucei‐specific DHODH inhibitor plus 5‐FU may prove to be an effective therapeutic strategy. We also show that this trypanosomal enzyme is inhibited by known inhibitors of bacterial Class 1A DHODH, in distinction to the sensitivity of DHODH from human and other higher eukaryotes. This selectivity is supported by the crystal structure of the T. brucei enzyme, which is reported here at a resolution of 1.95 Å. Additional research, guided by the crystal structure described herein, is needed to identify potent inhibitors of T. brucei DHODH.

15 January 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HTHari Babu Tatipaka
Hari Babu Tatipaka
JGJ. Robert Gillespie
J. Robert Gillespie
ACArnab K. Chatterjee
Arnab K. Chatterjee
NNNeil R. Norcross
Neil R. Norcross
MHMatthew A. Hulverson
Matthew A. Hulverson
Michael GelbMichael Gelb
Michael Gelb

19 December 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DPDonald A. Patrick
Donald A. Patrick
JGJ. Robert Gillespie
J. Robert Gillespie
JMJoshua McQueen
Joshua McQueen
MHMatthew A. Hulverson
Matthew A. Hulverson
RRRanae M. Ranade
Ranae M. Ranade
RTRichard R. Tidwell
Richard R. Tidwell

30 July 2017 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Open access
ABAndriy Buchynskyy
Andriy Buchynskyy
JGJ. Robert Gillespie
J. Robert Gillespie
ZHZackary Michel Herbst
Zackary Michel Herbst
RRRanae M. Ranade
Ranae M. Ranade
FBFrederick Buckner
Frederick Buckner
Michael GelbMichael Gelb
Michael Gelb
A high throughput screening and subsequent hit validation identified compound 1 as an inhibitor of Trypanosoma brucei parasite growth. Extensive structure–activity relationship optimization based on antiparasitic activity led to the highly potent compounds, 1-(4-fluorobenzyl)-3-(4-dimethylamino-3-chlorophenyl)-2-thiohydantoin (68) and 1-(2-chloro-4-fluorobenzyl)-3-(4-dimethylamino-3-methoxyphenyl)-2-thiohydantoin (76), with a T. brucei EC50 of 3 and 2 nM, respectively. This represents >100-fold improvement in potency compared to compound 1. In vivo efficacy experiments of 68 and 76 in an acute mouse model of Human African Trypanosomiasis showed a 100% cure rate after 4 days of oral treatment at 50 mg/kg twice per day.

19 October 2020 in ChemMedChem
Verified
Journal Article
Open access
PDF file
DSDaniel Gedder Silva
Daniel Gedder Silva
Anna JunkerAnna Junker
Anna Junker
SMShaiani M. G. de Melo
Shaiani M. G. de Melo
FFFernando Fumagalli
Fernando Fumagalli
JGJ. Robert Gillespie
J. Robert Gillespie
FEFlavio Emery
Flavio Emery
Neglected tropical diseases remain among the most critical public health concerns in Africa and South America. The drug treatments for these diseases are limited, which invariably leads to fatal cases. Hence, there is an urgent need for new antitrypanosomal drugs. To address this issue, a large number of diverse heterocyclic compounds were prepared. Straightforward synthetic approaches tolerated pre‐functionalized structures, giving rise to a structurally diverse set of analogs. We report on a set of 57 heterocyclic compounds with selective activity potential against kinetoplastid parasites. In general, 29 and 19 compounds of the total set could be defined as active against Trypanosoma cruzi and T. brucei brucei, respectively (antitrypanosomal activities <10 μM). The present work discusses the structure−activity relationships of new fused‐ring scaffolds based on imidazopyridine/pyrimidine and furopyridine cores. This library of compounds shows significant potential for anti‐trypanosomiases drug discovery.